Abstract: Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to a signal peptide.

Abstract: Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of an otoferlin protein, and the use of these compositions to treat hearing loss in a subject.

Abstract: Various example embodiments described herein relates, to an item manipulation system that can include a control system and an end effector. The end effector can include a tube defining a channel between a first end and a second end. The tube can include, a flexible suction cup that can be disposed within the channel of the tube. In some examples, the flexible suction cup can engage a surface of the item based on suction force generated through the flexible suction cup. The end effector also includes a linear actuator that can be mechanically coupled to the flexible suction cup. The end effector can be configured to: extend, the flexible suction cup towards the second end of the channel to position at least a portion of the flexible suction cup outside the tube and retract, the flexible suction cup within the channel to position the flexible suction cup within the tube.

Abstract: Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of an otoferlin protein, and the use of these compositions to treat hearing loss in a subject.

Abstract: Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of an otoferlin protein, and the use of these compositions to treat hearing loss in a subject.

Abstract: Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of an otoferlin protein, and the use of these compositions to treat hearing loss in a subject.

Abstract: Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of an otoferlin protein, and the use of these compositions to treat hearing loss in a subject.

Abstract: The present disclosure provides a construct comprising a coding sequence operably linked to a promoter, wherein the coding sequence encodes a vascular endothelial growth factor (VEGF) binding agent or a portion thereof. In some embodiments, a construct is an AAV construct. In some embodiments, an AAV construct is a part of an AAV particle. Compositions comprising constructs and AAV particles described herein can be useful in treating hearing loss, for example, hearing loss associated with vestibular schwannoma.

Abstract: Aspects of the disclosure include a power system comprising at least one three-wire active harmonic filter (AHF) configured to be coupled to, and provide compensation current to, a three-phase load, at least one four-wire AHF configured to be coupled to, and provide compensation current to, the three-phase load, and a controller configured to determine a total compensation current to provide to the three-phase load, the total compensation current including a zero component and a non-zero component, determine an output capacity of the at least one three-wire AHF and the at least one four-wire AHF, calculate a current-compensation ratio based on the output capacity of the at least one three-wire AHF and the at least one four-wire AHF, and control the at least one four-wire AHF to provide at least a portion of the non-zero component of the total compensation current to the three-phase load based on the current-compensation ratio.

Abstract: A check-in system for an dispensing items includes a computing device having an application installed thereon. The computing device is configured to check in a customer to notify the kiosk of a time range during which an order of the customer is picked up. The kiosk is configured to receive a check-in message from the computing device, receive the location of the computing device, receive a message indicative of the arrival of the customer at the automated tower, retrieve information of the order from an order database stored on a remote server, assemble the order based on the check-in message and the information of the order, and move the assembled order close to a pick-up location of the automated tower to facilitate pick-up of the assembled order.

Abstract: Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to a signal peptide.

Abstract: The present disclosure provides technologies comprising a polynucleotide capable of expressing and/or inhibiting a KCNQ4 gene product.

Abstract: The present disclosure provides constructs comprising a coding sequence operably linked to a promoter, wherein the coding sequence encodes a pendrin protein. Exemplary constructs include AAV constructs. Also provided are methods of using disclosed constructs for the treatment of hearing loss and/or deafness.

Abstract: The present disclosure provides constructs comprising a coding sequence operably linked to a promoter, wherein the coding sequence encodes a connexin 26 protein. Exemplary constructs include AAV constructs. Also provided are methods of using disclosed constructs for the treatment of hearing loss and/or deafness.

Abstract: Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of an otoferlin protein, and the use of these compositions to treat hearing loss in a subject.

Abstract: Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of an otoferlin protein, and the use of these compositions to treat hearing loss in a subject.

Abstract: Provided herein are compositions that include at least two different nucleic acid vectors that, when introduced into a primate cell, the at least two different vectors undergo con catamerization or homologous recombination with each other, thereby forming a recombined nucleic acid that encodes a full-length target protein (e.g., a supporting cell target protein or a hair cell target protein). Also provided are compositions that include a single AAV vector that, when introduced into a primate cell, a nucleic acid encoding a full-length target protein (e.g., a supporting cell target protein or a hair cell target protein) is generated at the locus of the supporting cell target gene, and the primate expresses the target protein (e.g., a supporting cell target protein or a hair cell target protein).

Abstract: The present disclosure provides thirteen synthetic peptides which have been shown to be FGF18 agonists. These synthetic peptides and topical compositions for decreasing, eliminating, or suppressing hair growth are disclosed herein. Methods for reducing hair growth, improving the appearance of skin, kits, and related cosmetic formulations are also provided herein.

Abstract: Compositions and topical formulations comprising a PPAR agonist complex comprising glyceryl linoleate, glyceryl linolenate, xymenynic acid, and Pterocarpus marsupium bark extract are described herein. Methods of inducing skin barrier repair, increasing the biosynthesis of barrier lipids and proteins in the skin, stimulating hair growth, treating acne and combinations thereof utilizing the composition and topical formulations are also provided herein.